Joseph Oliveto - 16 Apr 2026 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)

Reporting relationship: President and CEO, Director
Issuer ticker: MIST
Reported as of: 16 Apr 2026
Net transaction value: -$82,490
SEC form: 4
Accepted by SEC: 20 Apr 2026, 16:06:18 UTC
Prior SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Oliveto

Key filing fact

Joseph Oliveto filed Form 4 for Milestone Pharmaceuticals Inc. (MIST) on 20 Apr 2026.

Key facts

This page summarizes Joseph Oliveto's Form 4 filing for Milestone Pharmaceuticals Inc. (MIST).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Apr 2026, 16:06.

Change

Previous filing in this sequence was filed on 05 Feb 2026.
Current net transaction value: -$82,490.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001437782 Primary reporting owner

Oliveto Joseph

Relationship: President and CEO, Director
Address: C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, QUEBEC, CANADA
Signature: /s/ Joseph Oliveto
Signature date: 20 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIST transaction

Common Shares

Sale

Transaction value: $82,490
Shares: -36,500
Change %: -7.6%
Price: $2.26
Shares after: 446,244
Date: 16 Apr 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote.